NOF stock faces valuation split after 10% monthly rise
Published on 10/31/2026 at 00:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSValuation Debate And Business Mix
- Simply Wall St sees NOF as expensive on earnings multiples but below its discounted cash-flow estimate.
- The company combines chemicals with healthcare-related activities in Japan.
- NOF reported its fiscal-year financial report on October 1, covering the year ended March 31, 2026.
NOF stock has entered a fresh valuation debate after a monthly rebound, with investors weighing earnings multiples against projected cash generation. Simply Wall St published its analysis on October 26, 2026.
The analysis said NOF shares had gained 10.15 percent over 30 days to 2,838.5 Japanese yen, while the year-to-date performance remained negative. Its earnings-based view puts the stock at a price-to-earnings ratio of 16, above the Japanese chemicals industry average of 12.6 but below the peer-group average of 19.9.
Cash Flow And Earnings Diverge
That multiple leaves room for caution if chemicals demand weakens or healthcare-related earnings lose momentum. Simply Wall St calculated a fair price-to-earnings level of 14.8, indicating that the current earnings valuation could contract if investor confidence cools.
The same analysis reaches a more constructive conclusion through discounted cash flow. It places estimated future cash-flow value at 3,542.37 Japanese yen per share, above the cited market price. The contrasting signals make assumptions about growth, margins and capital allocation central to the investment case rather than allowing one valuation measure to decide the outlook.
Financial Reporting Sets The Next Reference Point
NOF's investor-relations page lists the publication of its 2026 financial report on October 1, covering the fiscal year ended March 31, 2026. The report provides the latest full-year reference for assessing whether the company's cash generation and profit profile support the valuation debate.
How NOF Competes
NOF Corporation manufactures chemicals in Japan and also has healthcare-related activities, giving it a broader platform than a narrowly focused specialist. Its mix places it alongside chemical and healthcare businesses such as Novo Nordisk and Biogen in comparative screens, although those companies have more specialized pharmaceutical profiles. NOF's positioning therefore depends on the balance between industrial chemicals and healthcare-linked growth rather than on a single product category.
NOF Corporation At A Glance
- Company: NOF Corporation
- ISIN: JP3753400005
- Ticker: 4403.T
- Home exchange: Tokyo Stock Exchange
- Business: Chemicals and healthcare-related activities
- Reference analysis: October 26, 2026
Japanese equities trade within the broader regional market backdrop tracked by the Nikkei 225.
More news and analyses on NOF stock.
